Hygiene and health company Essity has acquired the company Hydrofera. The company offers technology and products within advanced wound care. The purchase price amounts to USD 116m (approximately SEK 1.1bn) with a potential additional earnout amount of USD 15m (approximately SEK 137m) on a cash and debt free basis. The acquisition supports Essity's strategic priority to grow through acquisitions in Medical Solutions.

The US company Hydrofera was founded in 1996 and is a developer of Hydrofera Blue Antibacterial Wound Dressings, an advanced line of wound care products designed to shorten healing times, lower treatment costs, and deliver better patient outcomes. The company, which has about 90 employees, has its head office in Manchester, Connecticut and is present in more than 15 countries. 

For the first nine months of 2021, Hydrofera reported net sales of USD 20.7m (SEK 176m) with an EBITDA of USD 5,9m (SEK 50m), an EBITA of USD 5,6m (SEK 48m), equivalent to an EBITA margin of 27.2%. Sales growth for the first nine months of 2021 amounted to 22%. In 2020, the company reported net sales of approximately USD 23.5m (SEK 216m), with an EBITDA of USD 4.6m (SEK 42m) and EBITA of USD 4.3m (SEK 39m), equivalent to an EBITA margin of 18.1%. Sales growth in 2020 amounted to 13%. The acquisition is expected to be accretive to Essity's earnings per share in 2022.  

"The acquisition of Hydrofera is yet another great strategic fit for Essity further strengthening our innovation capacity and expanding our offering within advanced wound care. The company has innovations that significantly accelerate healing and reduce the patient's discomfort," says Ulrika Kolsrud, President Health and Medical Solutions at Essity. 

Hydrofera has a direct sales force and maintains agreements and preferred provider status with the major national medical/surgical distributors and buying groups in the US and Canadian healthcare markets. Products are used across the entire care range such as hospitals, wound clinics, long term care facilities and homecare. The suite of products is designed to meet requirements for a wide variety of wound care needs. 

Essity's medical solutions business offers innovative and high-quality medical products in wound care, compression, and orthopedics with global brands such as Leukoplast, Cutimed, JOBST, Actimove and Delta-Cast. In acute and advanced wound care, Essity is the world's fifth largest player. 

NB: This information is such that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 14:00 CET on December 29, 2021. 

Karl Stoltz, Media Relations Manager, +46 709 426 338

For further information, please contact:
Per Lorentz, Vice President Corporate Communications, +46 733 13 30 55, per.lorentz@essity.com
Johan Karlsson, Vice President Investor Relations, +46 705 11 15 81, johan.ir.karlsson@essity.com

Essity is a leading global hygiene and health company. We are dedicated to improving well-being through our products and services. Sales are conducted in approximately 150 countries under the leading global brands TENA and Tork, and other strong brands, such as JOBST, Leukoplast, Libero, Libresse, Lotus, Nosotras, Saba, Tempo, Vinda and Zewa. Essity has about 46,000 employees. Net sales in 2020 amounted to approximately SEK 122bn (EUR 11.6bn). The company's headquarters is located in Stockholm, Sweden, and Essity is listed on Nasdaq Stockholm. Essity breaks barriers to well-being and contributes to a healthy, sustainable and circular society. More information at www.essity.com.

https://news.cision.com/essity/r/essity-acquires-advanced-wound-care-company-in-us,c3479513

https://mb.cision.com/Main/15798/3479513/1515570.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English